Wells Fargo & Company Arca Biopharma, Inc. Transaction History

Wells Fargo & Company

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.71 - $4.0 $136 - $320	-80 Closed	0 $0
Q1 2024 May 10, 2024	BUY	$1.58 - $1.78 $1 - $1	1 Added 1.27%	80 $0
Q4 2023 Feb 09, 2024	BUY	$1.7 - $2.05 $6 - $8	4 Added 5.33%	79 $0
Q3 2023 Nov 13, 2023	SELL	$2.01 - $2.07 $58 - $60	-29 Reduced 27.88%	75 $0
Q2 2023 Aug 15, 2023	BUY	$1.94 - $2.11 $7 - $8	4 Added 4.0%	104 $0
Q1 2023 May 12, 2023	BUY	$1.99 - $2.55 $3 - $5	2 Added 2.04%	100 $0
Q4 2022 Feb 13, 2023	BUY	$1.86 - $25.8 $3 - $51	2 Added 2.08%	98 $0
Q2 2022 Aug 12, 2022	BUY	$2.2 - $2.53 $15 - $17	7 Added 7.87%	96 $0
Q1 2022 May 16, 2022	BUY	$1.77 - $2.49 $1 - $2	1 Added 1.14%	89 $0
Q3 2021 Nov 15, 2021	SELL	$2.77 - $3.74 $182 - $246	-66 Reduced 42.86%	88 $0
Q2 2021 Aug 16, 2021	BUY	$3.06 - $3.9 $287 - $366	94 Added 156.67%	154 $0
Q1 2021 May 13, 2021	SELL	$3.48 - $5.3 $3 - $5	-1 Reduced 1.64%	60 $0
Q4 2020 Feb 09, 2021	BUY	$3.74 - $5.18 $93 - $129	25 Added 69.44%	61 $0
Q3 2020 Nov 05, 2020	BUY	$4.07 - $7.99 $101 - $199	25 Added 227.27%	36 $0
Q1 2020 May 14, 2020	BUY	$2.32 - $6.42 $25 - $70	11 New	11 $0

280K

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.